News
-
-
-
PRESS RELEASE
Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030 -
PRESS RELEASE
Theranexus, Diverchim et l'INSERM bénéficient d'un financement de 4.7 millions d'euros dans le cadre de l'appel à projets " Innovations en Biothérapies et Bioproduction " de France 2030, pour développer un nouvel oligonucléotide antisens
Theranexus, Diverchim, and ARNA laboratory of INSERM receive 4.7 million euros from the French government to develop a groundbreaking autophagy activation therapy called PickASO -
-
-
PRESS RELEASE
Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults -
PRESS RELEASE
Theranexus et BBDF annoncent les données finales et positives de sécurité et d'efficacité de Batten-1 dans l'étude de phase 1/2
Theranexus et la Fondation BBDF annoncent des données positives sur la stabilisation des symptômes moteurs chez les patients jeunes adultes atteints de la maladie de Batten CLN3 après 18 mois de traitement -